Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC)

Acta Oncologica

Volumn 53, Issue 5, 2014, Pages 654-661

  Metwally, Mohamed A Hassan ^a   Frederiksen, Katrine Diemer ^b   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NIMORAZOLE; RADIOSENSITIZING AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CHEST TIGHTNESS; CLINICAL EVALUATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DENMARK; DEPRESSION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLUSHING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAUSEA; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; RISK; SENSORY NEUROPATHY; SIDE EFFECT; VERY ELDERLY; VOMITING; CARCINOMA, SQUAMOUS CELL; DOSE RESPONSE; HEAD AND NECK NEOPLASMS; MIDDLE AGED; DRUG TOLERANCE; NAUSEA AND VOMITING; PATIENT COMPLIANCE; RADIATION DOSE FRACTIONATION; RISK ASSESSMENT;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NIMORAZOLE; RADIATION-SENSITIZING AGENTS; RETROSPECTIVE STUDIES;

EID: 84921950369     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.864050     Document Type: Article

References (32)

1. Overgaard J. Hypoxic radiosensitization: Adored and ignored. J Clin Oncol 2007; 25: 4066-74.
2. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005; 77: 18-24.
3. Overgaard J. Clinical evaluation of nitroimidazoles as modi-fiers of hypoxia in solid tumors. Oncol Res 1994; 6: 509-18.
4. Horsman MR, Bohm L, Margison GP, Milas L, Rosier JF, Safrany G, et al. Tumor radiosensitizers-current status of development of various approaches: Report of an International Atomic Energy Agency meeting. Int J Radiat Oncol Biol Phys 2006; 64: 551-61.
5. Overgaard J, Andersen AP, J ø rgensen K, Ryg å rd J, Petersen M, Sand Hansen H. Misonidazole as an adjuvant to radiotherapy in the treatment of invasive carcinoma of the larynx and the pharynx; 2nd Interim analysis of the Danish Head and Neck Cancer study (DAHANCA)-Protocol 2. In: Progress in Radio-Oncology III. Kärcher K H, Kogelnik HD, Szepesi T, editors. Vienna: ICRO; 1987. p. 137-47.
6. Overgaard J, Overgaard M, Timothy AR. Studies of the pharmacokinetic properties of nimorazole. Br J Cancer 1983; 48: 27-34.
7. Overgaard J, Hansen HS, Andersen AP, Hjelm-Hansen M, J ø rgensen K, Sandberg E, et al. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: Report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 1989; 16: 1065-8.
8. Saunders ME, Dische S, Anderson P, Flockhart IR. The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum. Br J Cancer Suppl 1978; 3: 268-70.
9. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998; 46: 135-46.
10. Overgaard J, Sand Hansen H, Lindelov B, Overgaard M, J ø rgensen K, Rasmusson B, et al. Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother Oncol 1991; 20(Suppl 1): 143-9.
11. Richardson JL, Shelton DR, Krailo M, Levine AM. The effect of compliance with treatment on survival among patients with hematologic malignancies. J Clin Oncol 1990; 8: 356-64.
12. Haynes RB, Dantes R. Patient compliance and the conduct and interpretation of therapeutic trials. Control Clin Trials 1987; 8: 12-9.
13. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-Analysis. Lancet 2006; 368: 843-54.
14. Mendenhall WM, Riggs CE, Vaysberg M, Amdur RJ, Werning JW. Altered fractionation and adjuvant chemotherapy for head and neck squamous cell carcinoma. Head Neck 2010; 32: 939-45.
15. Marcu L, van DT, Olver I. Cisplatin and radiotherapy in the treatment of locally advanced head and neck cancer-A review of their cooperation. Acta Oncol 2003; 42: 315-25.
16. Homma A, Inamura N, Oridate N, Suzuki S, Hatakeyama H, Mizumachi T, et al. Concomitant weekly cisplatin and radiotherapy for head and neck cancer. Jpn J Clin Oncol 2011; 41: 980-6.
17. DAHANCA [Internet]. Danish Society for Head and Neck Oncology [updated 2013 Jul 10; cited 2013 Nov 5]. Available from: http://www.dahanca.dk/
18. Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003; 362: 933-40.
19. Paulson OB, Melgaard B, Hansen HS, Kamieniecka Z, Kohler O, Hansen JM, et al. Misonidazole neuropathy. Acta Neurol Scand Suppl 1984; 100: 133-6.
20. Timothy AR, Overgaard J, Overgaard M. A phase I clinical study of nimorazole as a hypoxic radiosensitizer. Int J Radiat Oncol Biol Phys 1984; 10: 1765-8.
21. Adams GE, Flockhart IR, Smithen CE, Stratford IJ, Wardman P, Watts ME. Electron-Affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. Radiat Res 1976; 67: 9-20.
22. Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin Oncol 2007; 19: 397-417.
23. Overgaard J, Overgaard M, Nielsen OS, Pedersen AK, Timothy AR. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br J Cancer 1982; 46: 904-11.
24. Saunders M, Dische S. Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. Br J Cancer Suppl 1996; 27: S271-8.
25. Cottrill CP, Bishop K, Walton MI, Henk JM. Pilot study of nimorazole as a hypoxic-cell sensitizer with the " chart " regimen in head and neck cancer. Int J Radiat Oncol Biol Phys 1998; 42: 807-10.
26. Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-A systematic review and meta-Analysis. Radiother Oncol 2011; 100: 22-32.
27. Henk JM, Bishop K, Shepherd SF. Treatment of head and neck cancer with CHART and nimorazole: Phase II study. Radiother Oncol 2003; 66: 65-70.
28. Bjarnason NH, Christiansen M, Specht L. The nimorazole regimen in patients with head and neck cancer can increase the effect of vitamin K antagonists. Acta Oncol 2008; 47: 150-1.
29. O'Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med 1976; 295: 354-7.
30. Schwartz RJ, Panacek EA. Basics of research (Part 7): Archival data research. Air Med J 1996; 15: 119-24.
31. Horwitz RI, Yu EC. Assessing the reliability of epidemiologic data obtained from medical records. J Chronic Dis 1984; 37: 825-31.
32. List MA, Stracks J, Colangelo L, Butler P, Ganzenko N, Lundy D, et al. How do head and neck cancer patients prioritize treatment outcomes before initiating treatment? J Clin Oncol 2000; 18: 877-84.